NasdaqHealth CareHealth Care SuppliesS&P MidCap 400
$9.46
-0.63 (-6.24%)
Close of Nov 06, 2026 · end-of-day data
XRAY 8-K filings in 2026
Every material Form 8-K Dentsply Sirona filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Dentsply Sirona reported third-quarter 2026 net sales of $836 million, down 7.6% from $904 million a year earlier, and adjusted EPS of $0.29, down 29.4% from $0.42. GAAP results improved from a year earlier, when large impairment charges produced a $427 million net loss attributable to the company, but the company's cash flow weakened and it updated its 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30.
Net sales were $836 million, down 7.6% as reported and down 7.0% in constant currency.
GAAP diluted loss was $0.01 per share, compared with a $2.14 loss per share a year earlier; adjusted EPS was $0.29 versus $0.42.
The 2026 outlook calls for approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding a $0.17 one-time benefit from tariff refunds.
Operating cash flow was $32 million versus $79 million, and free cash flow was $0 million versus $40 million; the company repurchased shares for approximately $13 million.
DENTSPLY SIRONA obtained lender consent and amended its revolving credit facility and three note purchase agreements, effective around September 30, 2026. The changes raise the maximum permitted leverage ratios for the quarters ending September 30 and December 31, 2026, and add tighter limits on new liens, subsidiary debt and restricted payments. The company says the revised terms are intended to keep it in compliance with its debt covenants in all material respects.
Maximum permitted Total Leverage Ratio and Senior Leverage Ratio increased for fiscal quarters ending September 30, 2026 and December 31, 2026.
Until the compliance certificate for fiscal 2026 is delivered, new liens and new subsidiary debt are generally prohibited, and restricted payments are limited with certain carveouts.
Credit facility adds a new pricing level for the applicable margin and facility fee; note interest increases if leverage meets specified thresholds.
Dentsply Sirona appointed John Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026, under an offer letter dated May 30, 2026. Fortson most recently served as President and CFO of Kymera International, and previously was CEO of Ingevity Corporation. The CFO change is a senior finance leadership transition, and the filing discloses his pay and sign-on terms.
Base salary of $780,000 with a target annual bonus of 85% of base salary, prorated for 2026
Beginning in 2027, annual equity award with a target grant date fair value of $2,500,000
Sign-on cash payment of $500,000 and sign-on equity award with a target grant date fair value of $700,000
Dentsply Sirona reported first-quarter 2026 net sales of $880 million, up 0.1% from $879 million a year earlier, but posted a GAAP net loss attributable to the company of $10 million, or $0.05 per diluted share, compared with net income of $20 million, or $0.10 per share, in the first quarter of 2025. Restructuring and other costs of $67 million and a $32 million tax benefit shaped the result, and adjusted EPS fell 39.0% to $0.27. The company kept its 2026 outlook for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
Net sales of $880 million, up 0.1% from $879 million; constant currency sales fell 6.7%
GAAP net loss attributable to Dentsply Sirona of $10 million, or $0.05 per diluted share, versus net income of $20 million, or $0.10, a year earlier
Adjusted EPS of $0.27 versus $0.44 a year earlier, down 39.0%; adjusted EBITDA of $129 million versus $168 million
2026 outlook maintained: net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50
Dentsply Sirona reported a fourth quarter and full-year 2025 net loss, with fourth-quarter net sales up 6.2% but full-year net sales down 3.0%. The company also eliminated its quarterly dividend, announced a restructuring plan, and set 2026 net sales and adjusted EPS outlooks below its 2025 adjusted EPS of $1.60, which matters to shareholders because the dividend is gone and the outlook implies lower per-share earnings.
Q4 2025 net sales were $961 million, up 6.2%, but the company posted a net loss of $146 million, or $0.74 per diluted share, driven by $144 million in net-of-tax goodwill and intangible impairments.
FY 2025 net sales were $3,680 million, down 3.0%, and the net loss was $598 million, or $3.00 per diluted share, compared with a $910 million loss in 2024.
FY 2026 outlook: net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50, versus FY 2025 adjusted EPS of $1.60.
The Board eliminated the quarterly cash dividend, which the company said will redirect capital to debt retirement and share repurchases; a restructuring plan carries $55 million to $65 million in charges and about $120 million in annualized
Dentsply Sirona's board increased its size from 11 to 13 seats and appointed James D. Forbes and Brian P. McKeon as directors, effective February 27, 2026. Director Willie A. Deese notified the board he will not seek reelection at the 2026 annual meeting, and the filing states this is not the result of any disagreement with the company. The changes are board governance updates with no financial figures disclosed.
Board size increased from 11 to 13 directors on February 23, 2026
James D. Forbes joins the Compensation & Human Capital Committee; Brian P. McKeon joins the Audit and Finance and Science and Technology committees
Willie A. Deese will not stand for reelection at the 2026 annual meeting, after about 15 years of service per the press release
Dentsply Sirona appointed Donald Zurbay, former President and CEO of Patterson Companies, to its Board of Directors effective January 10, 2026, increasing the board from 10 to 11 members. The company also formed an ad hoc Growth and Value Creation Committee, co-chaired by Chairman Gregory Lucier and CEO Daniel Scavilla, to oversee its Return-to-Growth action plan.
Donald J. Zurbay appointed to the Board effective January 10, 2026, and will serve on the Audit and Finance Committee
Board size increased from 10 to 11 members; Zurbay will serve until the 2026 annual meeting of stockholders
Ad hoc four-member Growth and Value Creation Committee co-chaired by Gregory Lucier and Daniel Scavilla
Committee will oversee the Return-to-Growth action plan first outlined on the November 7, 2025 third-quarter 2025 earnings call
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Dentsply Sirona filing is on SEC EDGAR ↗. 8-K briefs of other companies →